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Rivaroxaban, a specific FXa 
inhibitor, improved endothelium-
dependent relaxation of aortic 
segments in diabetic mice
phuong tran pham1, Daiju fukuda2, Shusuke Yagi1, Kenya Kusunose1, Hirotsugu Yamada3, 
takeshi Soeki1, Michio Shimabukuro  2,4 & Masataka Sata1
Activated factor X (FXa) plays a central role in the coagulation cascade, while it also mediates vascular 
function through activation of protease-activated receptors (PARs). Here, we examined whether 
inhibition of FXa by rivaroxaban, a direct FXa inhibitor, attenuates endothelial dysfunction in 
streptozotocin (STZ)-induced diabetic mice. Induction of diabetes increased the expression of a major 
FXa receptor, PAR2, in the aorta (P < 0.05). Administration of rivaroxaban (10 mg/kg/day) to diabetic 
wild-type (WT) mice for 3 weeks attenuated endothelial dysfunction as determined by acetylcholine-
dependent vasodilation compared with the control (P < 0.001), without alteration of blood glucose 
level. Rivaroxaban promoted eNOSSer1177 phosphorylation in the aorta (P < 0.001). Induction of diabetes 
to PAR2-deficient (PAR2−/−) mice did not affect endothelial function and eNOSSer1177 phosphorylation 
in the aorta compared with non-diabetic PAR2−/− mice. FXa or a PAR2 agonist significantly impaired 
endothelial function in aortic rings obtained from WT mice, but not in those from PAR2−/− mice. FXa 
promoted JNK phosphorylation (P < 0.01) and reduced eNOSSer1177 phosphorylation (P < 0.05) in 
human coronary artery endothelial cells (HCAEC). FXa-induced endothelial dysfunction in aortic rings 
(P < 0.001) and eNOSSer1177 phosphorylation (P < 0.05) in HCAEC were partially ameliorated by a JNK 
inhibitor. Rivaroxaban ameliorated diabetes-induced endothelial dysfunction. Our results suggest that 
FXa or PAR2 is a potential therapeutic target.
Accumulating evidence suggests that the blood coagulation system participates in various disease processes. 
Activated blood coagulation factor X (FXa) plays a central role in the coagulation cascade, while it also elicits 
various cellular responses in vascular cells through activation of protease activated receptors (PAR)1–5. PARs are 
a family of G protein-coupled, seven transmembrane domain receptors, which are activated following proteolytic 
cleavage of their extracellular N-terminus. Among the four subtypes of the PAR family, PAR2, one of the major 
receptors of FXa, is expressed in vascular cells and leukocytes, but not in platelets6–8. Previous studies have shown 
that PAR2 mediates a number of physiological and pathological processes such as inflammation, angiogenesis and 
vasoregulation9–14. Together with the clinical approval of direct FXa inhibitors, the role of FXa-PAR2 signaling in 
vascular regulation has attracted much attention. In fact, several clinical studies have shown that rivaroxaban, the 
first oral FXa inhibitor, reduced cardiovascular events in patients with coronary artery disease15,16. In addition to 
inhibition of the coagulation cascade, several basic research studies, including our own, suggested that vascular 
protective properties of rivaroxaban by inhibiting FXa might play a role in these results17–21.
The vascular complications associated with atherosclerosis are the most serious manifestations in patients 
with diabetes. Diabetes causes endothelial dysfunction characterized with increased platelet aggregation, coag-
ulation, and vascular tone, all of which associate with the initiation of atherosclerosis22. Numerous studies 
have demonstrated that hyperglycemia leads to an impairment of NO production and activity in patients with 
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diabetes, leading to the development of endothelial dysfunction22–25. Although multifactorial in etiology26, recent 
studies suggested involvement of coagulation factors in the regulation of endothelial function27. However, few 
studies have examined the role of FXa-PAR2 signaling in the development of endothelial dysfunction in a dia-
betic condition28–30. We, here, hypothesized that inhibition of FXa by rivaroxaban attenuates the development 
of endothelial dysfunction in a diabetic condition. To address this hypothesis, we administered rivaroxaban to 
diabetic wild-type (WT) mice, and examined vascular responses. We also examined vascular responses of aortic 
rings obtained from diabetic PAR2-deficient (PAR2−/−) mice, and performed in vitro experiments using human 
coronary artery endothelial cells (HCAEC) treated with FXa or a PAR2 agonist to investigate the underlying 
mechanisms. The results of our experiments indicated that rivaroxaban ameliorated diabetes-induced endothelial 
dysfunction and suggested that the inhibition of FXa or PAR2 contributes to this disease context.
Results
Expression of PAR2 in aorta increased in diabetic mice. We examined the expression of PAR2, a 
major receptor for FXa, in the thoracic aorta of diabetic WT mice. Diabetic mice had significantly higher expres-
sion of PAR2 in both RNA and protein levels compared with the non-diabetic group (Fig. 1A,B). These results 
indicated elevation of PAR2 expression under a hyperglycemic condition.
Rivaroxaban improved endothelial dysfunction in WT diabetic mice. We next investigated 
whether rivaroxaban ameliorates endothelial dysfunction in WT diabetic mice. Induction of diabetes impaired 
endothelium-dependent vasodilation in response to acetylcholine (Ach) (P < 0.001). However, rivaroxaban treat-
ment for 3 weeks significantly attenuated impairment of endothelial function in diabetic mice compared with 
non-treated mice (P < 0.01) (Fig. 2A). In contrast, endothelium-independent vascular response to sodium nitro-
prusside (SNP) did not differ between rivaroxaban-treated mice and non-treated mice (Fig. 2B). Administration 
of rivaroxaban for 3 weeks did not affect blood glucose level or total cholesterol level, although it reduced triglyc-
eride level in diabetic WT mice (Table 1). Consistent with the results of vascular reactivity analyses, the results of 
western blotting using abdominal aorta showed that phosphorylation of eNOSSer1177 was significantly promoted 
in the rivaroxaban-treated group compared with the non-treated group (P < 0.05) (Fig. 2C). These results suggest 
that rivaroxaban, a direct FXa inhibitor, attenuates endothelial dysfunction in diabetic WT mice.
FXa induced endothelial dysfunction via JNK pathway. Rivaroxaban is an inhibitor of FXa. To inves-
tigate the effect of FXa on endothelial function, we performed western blot analysis using HCAEC. FXa promoted 
phosphorylation of JNK in HCAEC (P < 0.01) (Fig. 3A). FXa reduced phosphorylation of eNOSSer1177 (P < 0.05), 
which was attenuated by SP600125, a JNK inhibitor (P < 0.05) in this cell-type (Fig. 3B). We further performed ex 
vivo experiments using aortic rings obtained from WT mice. FXa significantly impaired endothelium-dependent 
vascular reactivity in response to Ach (P < 0.001), while SP600125 ameliorated FXa-induced endothelial dys-
function (P < 0.001) (Fig. 3C). Neither FXa nor SP600125 affected endothelium-independent vasodilation in 
response to SNP (Fig. 3D). These results suggest that FXa induced endothelial dysfunction, at least partially, via 
the JNK pathway.
Figure 1. Induction of diabetes increased expression of PAR2 in aorta. (A) qPCR analysis using thoracic aorta 
demonstrated that induction of diabetes by STZ increased the expression of PAR2 (n = 6). (B) Western blot data 
demonstrated that induction of diabetes increased the expression of PAR2 in the aorta (n = 8–10). *P < 0.05. All 
values are mean ± SEM.
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Figure 2. Rivaroxaban attenuated endothelial dysfunction in diabetic mice. (A,B) Induction of diabetes by 
STZ impaired endothelium-dependent vasodilation in response to Ach compared with the non-diabetes group. 
Rivaroxaban administration to diabetic mice for 3 weeks ameliorated endothelial function compared with the 
non-treated group (A). Vasorelaxation in response to SNP did not differ among the three groups (B) (n = 8–12). 
***P < 0.001 vs. NT, and ††P < 0.01 vs. STZ. (C) Induction of diabetes attenuated eNOS phosphorylation at 
Ser1177; however, rivaroxaban treatment ameliorated this response (n = 10–13). There was no significant 
difference in total eNOS expression among 3 groups. *P < 0.05. All values are mean ± SEM.
NT (n = 12) STZ (n = 13) STZ + Riv (n = 10) P-value
Body weight, g 26.5 ± 0.8 17.5 ± 0.5*** 16.9 ± 0.5*** <0.001
Blood glucose, mg/dl 166.8 ± 5.3 641.5 ± 27.6*** 607.1 ± 23.4*** <0.001
Total cholesterol, mg/dl 115.8 ± 2.0 358.9 ± 17.0*** 441.8 ± 78.4*** <0.001
Triglyceride, mg/dl 137.1 ± 12.3 346.2 ± 51.8 133.2 ± 55.6†† <0.01
HDL-cholesterol, mg/dl 75.5 ± 1.9 161.5 ± 4.2*** 145 ± 12.9*** <0.001
Table 1. Effect of rivaroxaban on metabolic parameters. NT; non-treatment, STZ; streptozotocin, Riv; 
rivaroxaban, HDL; high-density lipoprotein. ***P < 0.001 vs. NT, and ††P < 0.01 vs. STZ.
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FXa and PAR2 is associated with endothelial dysfunction in diabetic condition. PAR2 is a major 
receptor of FXa. Therefore, to investigate the role of PAR2 in the development of endothelial dysfunction in 
diabetic mice, we induced diabetes in WT and PAR2−/− mice by STZ injection and examined vascular response. 
Induction of diabetes significantly impaired endothelial function as determined by Ach-dependent vasodilation 
in WT mice but not in PAR2−/− mice (Fig. 4A). STZ injection elevated blood glucose and lipid levels in both 
strains of mouse; however, there were no significant differences between non-diabetic WT mice and PAR2−/− 
mice or between diabetic WT mice and PAR2−/− mice (Table 2). Endothelium-independent vascular response to 
SNP did not differ between groups (Fig. 4B). The results of western blotting using abdominal aorta demonstrated 
no significant differences in the phosphorylation of eNOSSer1177 and JNK between diabetic and non-diabetic 
PAR2−/− mice (Fig. 4C,D). We also examined the role of PAR2 in endothelial function. FXa impaired endothelial 
function of aortic rings from WT mice (Fig. 3C); however, this response was not observed in aortic rings from 
PAR2−/− mice (Fig. 5A). FXa did not affect endothelium-independent vasodilation (Fig. 5B). We further exam-
ined the effect of pharmacological activation of PAR2 using a specific PAR2 agonist, AP-II. Incubation with AP-II 
significantly impaired endothelium-dependent vasodilation of aortic rings from WT mice (P < 0.001) but not of 
aortic rings from PAR2−/− mice (Fig. 5C). AP-II did not affect endothelium-independent vasodilation of aortic 
rings from both strains of mouse (Fig. 5D). In addition, we examined effects of rivaroxaban on FXa-induced 
endothelial dysfunction. Rivaroxaban ameliorated FXa-induced endothelial dysfunction. Rivaroxaban did not 
have effects on endothelial dysfunction induced by AP-II or H2O2 (Fig. 6). These results suggest that FXa-PAR2 
signaling contributes, at least partially, to the development of endothelial dysfunction.
Figure 3. JNK inhibitor attenuated endothelial dysfunction induced by FXa. (A) FXa promoted the 
phosphorylation of JNK in HCAEC (n = 9). **P < 0.01. (B) FXa attenuated the phosphorylation of eNOS at 
Ser1177 in HCAEC. Pretreatment with SP600125, a JNK inhibitor, ameliorated this response (n = 9). *P < 0.05. 
(C,D) Vascular reactivity in response to Ach (C) or SNP (D) was examined using aortic segments obtained 
from WT mice (n = 5–12). FXa impaired endothelium-dependent vasodilation in response to Ach. SP600125 
attenuated endothelial dysfunction induced by FXa. H2O2 was used for showing the impaired endothelial 
dysfunction. Vasorelaxation in response to SNP did not differ in the presence of FXa or SP600125. ***P < 0.001 
vs. NT, and †††P < 0.001 vs. FXa. All values are mean ± SEM.
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Discussion
Accumulating evidence suggests that FXa-PAR2 signaling contributes to various pathological conditions31–34. 
In this study, we found that rivaroxaban, a FXa inhibitor, significantly attenuated endothelial dysfunction in 
diabetic WT mice, with no alteration of blood glucose level. On the other hand, FXa or AP-II impaired 
Figure 4. Genetic deletion of PAR2 prevented endothelial dysfunction caused by diabetes. (A,B) Vascular 
reactivity in response to Ach (A) or SNP (B) was examined using aortic segments obtained from diabetic 
or non-diabetic mice (n = 8–14). Induction of diabetes impaired endothelial function determined by the 
response to Ach in WT mice. Induction of diabetes to PAR2−/− mice did not affect vascular response to Ach or 
SNP. ***P < 0.001 vs. non-diabetic WT mice. (C,D) Induction of diabetes in PAR2−/− mice did not affect the 
phosphorylation of eNOSSer1177 (C) and JNK (D) (n = 6). There was no significant difference in total eNOS and 
JNK expression between 2 groups. All values are mean ± SEM.
WT PAR2−/−
NT
(n = 14)
STZ
(n = 9)
NT
(n = 9)
STZ
(n = 8)
Body weight, gram 26.2 ± 0.4 17.3 ± 0.7*** 26.2 ± 1.2 17.3 ± 0.5***
Blood glucose, mg/dl 151.4 ± 6.8 630.4 ± 28.1*** 135.2 ± 8.5 507.8 ± 29.7***
Total cholesterol, mg/dl 110.2 ± 3.0 439.9 ± 88.3*** 117.6 ± 3.5 417.1 ± 33.7***
Triglyceride, mg/dl 114.9 ± 8.9 403.1 ± 110.3** 141.3 ± 30.5 461.5 ± 100.5**
HDL-Cholesterol, mg/dl 67.7 ± 1.9 149.8 ± 15.3*** 74.6 ± 2.3 153.1 ± 7.6***
Table 2. Effect of STZ injection on metabolic parameters. WT; wild-type, NT; non-treatment, STZ; 
streptozotocin,HDL; high-density lipoprotein. *P < 0.05, **P < 0.01, and ***P < 0.001 vs. NT.
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endothelium-dependent vasodilation of aortic segments obtained from WT mice. Furthermore, rivaroxaban 
ameliorated endothelial dysfunction induced by FXa but not AP-II. In addition, induction of diabetes in PAR2−/− 
mice did not impair endothelial function. Also, neither FXa nor AP-II affected endothelial function of aortic 
segments obtained from PAR2−/− mice. The results of in vitro experiments using HCAEC indicated that FXa 
causes endothelial dysfunction as determined by eNOSSer1177 phosphorylation, partially through JNK signaling, 
supporting the in vivo results. These results indicated that rivaroxaban ameliorates diabetes-related endothelial 
dysfunction and suggested that the inhibition of FXa or PAR2 plays a role as an underlying mechanism at least 
partially.
Rivaroxaban is the first oral anticoagulant that directly inhibits FXa and suppresses thrombin formation. 
Thrombin plays a pivotal role not only in the blood coagulation cascade, but also in vasoregulation by activating 
multiple cell types in the vasculature such as endothelial cells, smooth muscle cells, and macrophages. Recent 
clinical trials demonstrated that patients with coronary artery disease treated with rivaroxaban experienced fewer 
cardiovascular events compared with the control15,16. The anti-coagulation effects of rivaroxaban might play a 
role in these results, although these studies also suggest that the inhibition of FXa by rivaroxaban might improve 
vascular function.
FXa activates PAR1 and PAR26–8. Because of its unique expression pattern, previous studies investigated the 
role of PAR2 in vascular function17,19,20,35. We and others have demonstrated that inhibition of FXa-PAR2 signa-
ling by FXa inhibitors including rivaroxaban or genetic deletion of PAR2 attenuates atherogenesis in atheroscle-
rotic mouse models17,20. Endothelial function is essential for homeostasis of the vasculature, and its impairment 
initiates atherosclerotic changes36. In diabetic patients, endothelial function was impaired by one or a combi-
nation of factors such as hyperglycemia, fatty acids, inflammation, and insulin resistance. In parallel, previous 
studies indicated that endothelial dysfunction is reversible and a potential therapeutic target in atherosclerotic 
disease37,38. Therefore, in this study, we investigated the effect of rivaroxaban on diabetes-related endothelial dys-
function. Previous studies have shown vasoprotective effects of rivaroxaban. Rivaroxaban enhanced viability, 
growth and migration of endothelial cells, suggesting its protective effects on endothelium39. Rivaroxaban also 
Figure 5. Activation of PAR2 impaired endothelial function. (A,B) Vascular reactivity in response to Ach 
(A) or SNP (B) was examined using aortic segments obtained from WT mice or PAR2−/− mice (n = 6–11). 
FXa did not impair endothelium-dependent (A) and -independent (B) vascular response in aortic segments 
obtained from PAR2−/− mice. H2O2 was used for showing the impaired endothelial dysfunction in WT mice. 
***P < 0.001 vs. WT + NT. (C,D) Vascular reactivity to AP-II, a specific agonist for PAR2, was determined 
using aortic segments isolated from WT and PAR2−/− mice (n = 5–7). AP-II impaired endothelium-dependent 
vasodilation in response to Ach in aortic segments obtained from WT mice. However, AP-II did not affect 
endothelial function in aortic segments obtained from PAR2−/− mice (C). AP-II did not affect vasorelaxation 
in response to SNP in aortic segments obtained from both strains of mouse (D). ***P < 0.001 vs. WT + NT. All 
values are mean ± SEM.
7Scientific RepoRtS |         (2019) 9:11206  | https://doi.org/10.1038/s41598-019-47474-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
decreased FXa-induced cell senescence of endothelial cells and endothelial progenitor cells, accelerating neo-
vascularization in the ischemic limb40. Several previous studies using diabetic mouse models demonstrated that 
rivaroxaban promoted vessel formation41, and that a PAR2 antagonist reduced endothelial dysfunction42. In this 
study, we demonstrated that both rivaroxaban, a clinically approved FXa inhibitor, and genetic deletion of PAR2 
clearly attenuated the development of endothelial dysfunction in diabetic mice, without alteration of blood glu-
cose level. On the other hand, FXa or AP-II attenuated endothelial function of aortic rings, supporting our in vivo 
results. In addition, our in vitro experiments using HCAEC demonstrated that FXa reduced phosphorylation of 
eNOSSer1177 partially through JNK activation. In fact, a JNK inhibitor ameliorated FXa-induced impairment of 
endothelium-dependent vascular response. JNK activation is essential for endothelial dysfunction by inhibiting 
eNOSSer1177 phosphorylation43,44. Previous studies showed that PAR2 activation enhances the phosphorylation of 
JNK in several cell types including endothelial cells32,45–47. Thus, our study indicates the involvement of FXa-PAR2 
signaling, at least partially, as an underlying mechanism in diabetes-related endothelial dysfunction. The signal-
ing pathways associated with PARs are not fully understood. Therefore, further studies are required to elucidate 
the precise mechanism by which FXa-PAR2 signaling causes endothelial dysfunction.
Recent studies including our present study showed that inhibition of FXa-PAR2 signaling has protective effects 
on the endothelium. However, several previous studies have demonstrated protective roles of PAR2 in vascular 
function. For example, studies using a septic shock model showed protective roles of FXa in vascular inflamma-
tion and vascular response48,49. Other studies demonstrated the angiogenic potential of PAR211,50. Furthermore, 
one study demonstrated that PAR2 mediates arterial vasodilation in diabetes51. Because previous studies sug-
gested that the function or signaling of PAR2 may vary depending on disease context14,52, the differences in mouse 
Figure 6. Rivaroxaban ameliorated FXa-induced endothelial dysfunction. Rivaroxaban ameliorated FXa-
induced endothelial dysfunction (A), although it did not have effects on endothelial dysfunction induced by 
AP-II (C) or H2O2 (E). Rivaroxaban did not affect endothelial-independent vascular response induced by FXa 
(B), AP-II (D), or H2O2 (F) (n = 4–7). †††P < 0.001 vs. FXa. All values are mean ± SEM.
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model and strategy for PAR2 inhibition may explain the discrepancy among these studies. Dissecting the role of 
FXa-PAR2 signaling in vascular function and its signaling mechanisms requires further studies.
There are several limitations of our study. First, we did not examine the plasma concentration of rivaroxaban 
in this study. However, we did not observe any bleeding complication throughout the study period in the treated 
mice. Secondly, FXa activates PAR1 as well as PAR2, although we focused only on the role of PAR2 in this study. 
PAR1 might contribute to the result of this study. Also, we used systemic deletion model of PAR2 in this study. 
Smooth muscle cells and leukocytes express PAR26,7. Therefore, the activation of PAR2 on these cell types might 
participate in our results. Thirdly, we observed a reduction of triglyceride by the administration of rivaroxaban 
in STZ-induced diabetic WT mice. In our previous studies, rivaroxaban did not reduce triglyceride level in WT 
mice and apolipoprotein e-deficient mice. Triglyceride level in STZ-induced diabetic WT mice was shown to 
be higher than that in non-diabetic mice in other studies53. The results of the present study might be because 
of the mouse model we used. Further studies are needed in relation to this. Fourthly, we did not examine dose 
dependent effects and effects of other FXa inhibitor. These investigations would provide stronger evidence for the 
effectiveness of rivaroxaban or FXa inhibition on diabetes-induced endothelial dysfunction. Last, the results of 
our present study were obtained from only basic studies. Therefore, the results of our study might not applied to 
clinical situation directly. On the other hand, we showed that clinically approved rivaroxaban, a FXa inhibitor, 
inhibited the development of diabetes-induced endothelial dysfunction. Together with our previous studies that 
reported atheroprotective effects of rivaroxaban, the results of our present study might explain one of the mecha-
nisms for recent clinical studies that reported fewer cardiovascular events in patients with coronary artery disease 
treated with rivaroxaban compared with the control15,16. Also, we used not only pharmacological blockade of FXa 
by using rivaroxaban but also PAR2 deficient mouse model or ex vivo vascular reactivity experiments using AP-II. 
These experiments allowed us to examine the effects of FXa or PAR2 from multiple aspects. We thought that these 
are the strength of our present study.
In conclusion, our study demonstrated that rivaroxaban attenuated the development of endothelial dysfunc-
tion in diabetic mice, independently of blood glucose level, possibly through partial inhibition of FXa-PAR2 
signaling. Rivaroxaban may provide a therapeutic option for diabetes-related endothelial dysfunction, and FXa 
and/or PAR2 might be a potential therapeutic target for this disease condition.
Materials and Methods
Animal and drug administration. C57BL/6J wild-type mice and PAR2−/− mice (C57BL/6J background) 
were purchased from Japan SLC, Inc. and Jackson Laboratory, respectively. Diabetes was induced by a single 
intraperitoneal injection of streptozotocin (SZT, 180 mg/kg) to 8-week-old male mice after overnight fasting. The 
non-diabetic control group received an injection of vehicle (0.1 M sodium citrate). Rivaroxaban (10 mg/kg/day) 
supplemented to normal chow was administered for 3 weeks, immediately after STZ injection. The non-treated 
group received non-supplemented chow. Rivaroxaban was supplied by Bayer Pharma AG. Mice were housed in 
a room in which the temperature was kept at 23 °C and the light cycle was automatically controlled (12 hours 
dark/light). All procedures for animal experiments conformed to the guidelines for animal experimentation of 
Tokushima University. The protocol was reviewed and approved by the Animal Care and Use Committee of 
Tokushima University under #T29-113.
Blood glucose level and laboratory data. Glucose levels in tail vein blood were measured using 
Startstrip XP2 (NIPRO) at three time points: before fasting, day 3 after injection to confirm a diabetic condition, 
and at the time of harvest. Blood was collected from the left ventricle into EDTA-containing tubes. Plasma was 
separated from whole blood at 9000 rpm for 15 minutes at 4 °C and kept at −80 °C until required. Plasma lipid 
levels (e.g., total cholesterol, HDL-cholesterol, and triglyceride) were measured at LSI Medience Corporation 
(Japan).
Aorta preparation and vascular reactivity assay. At 3 weeks after the initiation of rivaroxaban admin-
istration, mice were sacrificed by an overdose of pentobarbital, and perfused with 0.9% sodium chloride solution 
via the left ventricle at constant pressure. The whole aorta was immediately isolated, and fat and connective tissue 
around the aorta were carefully removed. Aortic rings of 1.5 to 2 mm were cut from the thoracic aorta for vascular 
reactivity analysis. The remaining part of the thoracic aorta and the abdominal aorta were snap-frozen in liquid 
nitrogen for gene expression or western blotting analysis, respectively.
Vascular reactivity was examined as described previously54. Aortic rings were placed in organ baths filled 
modified Krebs-Henseleit buffer (118.4 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 
25 mM NaHCO3, 11.1 mM glucose) that was aerated (95% O2, 5% CO2) and warmed (37 °C). Changes in isomet-
ric tension were recorded on a polygraph (LabChart). The viability of aortic segments was tested with 31.4 mM 
KCl. To determine the relaxation response, the aortic rings were contracted with phenylephrine (10−9 to 10−4 M) 
to submaximal tension (60% of maximum). After stable contraction was determined, the rings were exposed to 
increasing concentrations of acetylcholine (Ach; 10−9 to 10−4 M) and SNP (10−9 to 10−4 M) to obtain a cumulative 
concentration-response curve. In ex-vivo experiments, aortic segments were pre-treated with 100 nM SP600126 
(Sigma Aldrich), a JNK inhibitor, for 2 hours, and then incubated with 10 nM mouse FXa (Heamatologic 
Technologies, Inc.) for 4 hours before analyses of vascular reactivity. To investigate the role of PAR2 in vascular 
function, aortic segments were incubated with 10 nM AP-II (Sigma Aldrich), a PAR-2 agonist, for 16 hours. In 
some experiments, H2O2 was used for the induction of endothelial dysfunction. To investigate the effect of rivar-
oxaban on FXa or AP-II, we pre-treated with aortic rings with 1 μM rivaroxaban for 16 hours.
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Cell culture. HCAEC were purchased from Lifeline cell Technology and cultured in EGM-2 (Lonza) in a 5% 
CO2 humidified atmosphere. To investigate the effect of FXa on endothelial cells, HCAEC (passages 4-6) were 
treated with 10 nM human Factor X (Heamatologic Technologies, Inc.) in EBM-2 (Lonza) containing 2% FBS for 
1 hour. In addition, to block the JNK pathway, HCAEC were pre-treated with 100 nM SP600125 for 2 hours, and 
then stimulated with human FXa for 1 hour.
Western blotting analysis. Total protein was exacted from cells or aortic tissue using RIPA buffer (Wako 
Pure Chemical Industries, Ltd.) containing a protease inhibitor cocktail (Roche) and phosphatase inhibitors 
(Roche). The concentration of protein was determined using a BCA protein assay kit (Thermo Scientific). Equal 
quantities of protein (10 μg) were separated using 7.5% sulfate–polyacrylamide gel and transferred onto polyvi-
nylidene difluoride membranes. After blocking with 5% bovine serum albumin, the membranes were incubated 
with a primary antibody; anti-phosphorylated eNOSSer1177, anti-eNOS (BD Biosciences), anti-phosphorylated 
JNK, or anti-JNK (Cell Signaling Technology), overnight at 4 °C. For detection of β-actin, the membranes were 
blocked with 5% skimmed milk and incubated with anti-β-actin antibody (Sigma) for 1 hour at room tempera-
ture. HRP-conjugated anti-mouse Ig or anti-rabbit Ig was used as a second antibody. Immunoblotting was ana-
lyzed with ECL-plus reagent (GE Healthcare) using a luminescent image analyzer (LAS-4000 mini, Fuji Film).
Quantitative Real-time PCR. An Illustra RNAspin RNA Isolation Kit (GE Healthcare) was used to extract 
total RNA from tissues. A QuantiTecht Reverse Transcription Kit (Qiagen) was used for synthesis of cDNA from 
100 ng RNA. Mx3000P (Agilent Technologies) and Power SYBR Green PCR master mix (Applied Biosystems) 
were used for quantitative real-time PCR. The following oligonucleotide primers were used: PAR2, forward: 
5′-GGACCGAGAACCTTGCAC-3′ and reverse: 5′-GAACCCCTTTCCCAGTGATT-3′ and β-actin: forward: 
5′-CCTGAGCGCAAGTACTCTGTGT-3′ and reverse: 5′-GCTGATCCACATCTGCTGGAA-3′. β-actin was 
used as the reference gene.
Statistical analyses. All data were presented as mean ± SEM. Comparison of parameters between 
two groups was performed with unpaired Student’s t-test when data showed a normal distribution or with 
Mann-Whitney U test when data did not show a normal distribution. Differences between multiple groups 
were analyzed by ANOVA followed by Tukey’s post hoc analysis when data showed a normal distribution or 
with Kruskal–Wallis test followed by Dunn’s post hoc analysis when data did not show a normal distribution. 
Comparison of dose-response curves was performed by two-factor repeated measures ANOVA, followed by 
Tukey’s post hoc test for comparison between groups. P < 0.05 was considered statistically significant.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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